A novel glioblastoma cancer gene therapy using AAV-mediated long-term expression of human TERT C-terminal polypeptide

Area of Science:

• Oncology
• Molecular Biology
• Gene Therapy

Background:

• Glioblastoma multiforme is an aggressive brain tumor with limited treatment options.
• Overexpression of hTERTC27 previously inhibited cervical cancer cell growth.
• This study investigates hTERTC27's therapeutic potential in glioblastoma models.

Purpose of the Study:

• To evaluate the in vivo therapeutic efficacy of hTERTC27 gene therapy in glioblastoma xenografts.
• To elucidate the molecular mechanisms underlying hTERTC27-mediated antitumor effects.

Main Methods:

• Intratumoral injection of adeno-associated virus carrying hTERTC27 (rAAV-hTERTC27) in nude mice with glioblastoma xenografts.
• Histological analysis of tumor tissues to assess necrosis, apoptosis, immune cell infiltration, and microvessel density.
• DNA microarray analysis of gene expression profiles in treated tumor tissues and cell lines.

Main Results:

• rAAV-hTERTC27 significantly reduced glioblastoma tumor growth.
• Treatment induced tumor necrosis, apoptosis, polymorphonuclear neutrophil infiltration, and decreased microvessel density.
• Gene expression analysis revealed complex mechanisms involving apoptosis, cell adhesion, immune response, and telomere maintenance genes.

Conclusions:

• hTERTC27 gene therapy is a potent strategy against glioblastoma.
• The therapeutic effects involve multifaceted molecular pathways, including those regulating cell death and immune responses.
• Further research into hTERTC27's mechanisms could lead to novel glioblastoma treatments.